Skip to content

Innovative, Accessible Treatments For The Leading Causes Of Death Globally

At George Medicines, we believe single-pill fixed dose combinations of existing medicines offer the potential to better manage non-communicable diseases and could have a huge positive social impact by improving lives and reducing the financial burden on patients and health systems.

About Us +

Welcome to
George Medicines

Multiple drugs are increasingly being prescribed to adequately control conditions such as hypertension, cardiovascular disease and type 2 diabetes. This can be complicated for patients and costly for health systems. At George Medicines we are using our drug development expertise and the latest formulation approaches to combine existing medicines into novel single-pill therapies with the potential to bring significant improvements in clinical outcomes and adherence.

Our Approach +

About Us

George Medicines is a late-stage drug development company focused on improving the management of non-communicable diseases with innovative single-pill combinations of existing medicines. By combining best-in-class molecules from existing medicines in proprietary low-dose formulations, George Medicines is aiming to develop innovative treatments with the potential to be more efficacious, safer and more accessible than currently available treatment options.


Our Approach

George Medicines is a venture-backed spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes in non-communicable diseases. Our differentiated business model avoids the early, high-risk stages of drug discovery and development by formulating established drugs into innovative, single-pill combinations using proprietary technology, which reduces time-to-market and brings a higher probability of success while requiring less capital investment than is usual in the industry.



We are building a strong and diversified proprietary pipeline of innovative single-pill combination therapies in late-stage development, targeting some of the leading causes of death in both developed and developing countries, including hypertension, cardiovascular disease and type 2 diabetes.



Our strategy is to advance our late-stage pipeline through the final stages of development and to secure approval from global regulators. We work alongside appropriate partners to commercialise our therapies across the developed and developing world where our medicines can reduce the burden on health systems and have the biggest positive social impact.


Latest News


Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

500 UK patients to be treated as part of global trial Investigational single-pill combination offers potential to substantially increase efficacy and improve adherence to treatment, while minimising side effects London, UK, January 17 2022 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, …


George Medicines appoints Dr Charmaine Gittleson as Non-Executive Director

London, UK, 12 July 2021 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, today announces the appointment of Dr Charmaine Gittleson to the Board as Independent Non-Executive Director. Dr Gittleson has extensive international experience as a pharmaceutical physician and enterprise leader. Prior …


George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension

Novel proprietary triple low-dose combination pill has been shown to outperform traditional blood pressure treatments without additional side effects in earlier clinical research. Lead candidate in Company’s pipeline of proprietary fixed-dose combination therapies targeting high unmet need in large patient populations suffering from non-communicable diseases such as CVD and Diabetes. London, UK, 1 July 2021 …


George Medicines appoints Stefan König as Chief Executive Officer

Mr König joins to lead late-stage drug development company developing proprietary fixed dose combination therapies for non-communicable diseases. US FDA grants IND authorization to commence Phase III trials with triple combination candidate for the treatment of hypertension. Chief Business Officer, Karl Roberts, appointed to new role of Chief Operating Officer. London, UK, 3 June 2021 – …


Chairman’s Statement

“George Medicines is uniquely positioned to change the lives of the more than 2 billion people around the world suffering from non-communicable diseases with our novel single-pill therapies. By targeting underserved populations in established and emerging markets, we are making better medicines for all. And never was it more urgent, as the pandemic has highlighted weaknesses and inequalities in health systems globally”

Professor Stephen MacMahon AO, Chairman, Board of George Medicines

Part of a mission to deliver affordable and scalable treatments and technologies

George Medicines is one of George Health’s four businesses, created to commercialise medicines and technologies that leverage the George Institute’s late-stage clinical research for chronic disease.



Science, service, solutions. A leading CRO in Asia-Pacific with global capabilities


Science, service, solutions. A leading CRO in Asia-Pacific with global capabilities

George Health Technology

Affordable, personalised digital health care for all.

Ellen Medical Devices

The world’s first affordable dialysis system